Objective: S-(2-succinyl)cysteine (2SC) is formed by a Michael addition reaction between the Krebs cycle intermediate, fumarate, and cysteine residues in protein. We have investigated the role of fumarate in chemical modification and inhibition of the sulfhydryl enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in vitro and in tissues of diabetic rats. Research Design and Methods: GAPDH was incubated with fumarate in phosphate buffer to assess effects of fumarate on enzyme activity in vitro. Sites of 2SC formation were determined by analysis of tryptic peptides by HPLC-quadrupole-time of flight (QTOF) mass spectrometry (MS). 2SC and fumarate in gastrocnemius muscle of control and streptozotocin-induced diabetic rats were measured by LC/MS/MS and GC/MS, respectively. GAPDH was isolated from muscle by immunoprecipitation, and sites of modification of GAPDH were determined by MS analysis.
ncreased chemical modification of proteins as a result of oxidative stress is implicated in the pathogenesis of chronic diseases, including diabetes, atherosclerosis and Alzheimer's disease (1, 2) . In diabetes, oxidative damage is amplified by the accumulation of advanced glycation and lipoxidation endproducts (AGE/ALEs) in tissue proteins (3) , which bind to scavenger receptors and the receptor for AGE (RAGE) and induce inflammatory responses. (4) . Research on the chemistry of AGE/ALE formation in diabetes has focused primarily on modification of lysine and arginine residues in protein (3, 5, 6) . However, sulfhydryl groups on intracellular proteins are more nucleophilic than the amino or guanidino groups, suggesting that cysteine modifications should also be abundant. We have recently identified S-(2-succinyl)cysteine (2SC) as a chemical modification of plasma and tissue proteins, formed by a Michael addition reaction of fumarate with cysteine (7) (Scheme 1). We also showed that 2SC was significantly increased in muscle protein of diabetic vs. control rats and that fumarate irreversibly inhibited several sulfhydryl enzymes in vitro, including glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Brownlee and colleagues (1, (8) (9) (10) ) have proposed that, during hyperglycemia in diabetes, inhibition of GAPDH during oxidative stress is a critical step in the development of diabetic complications.
According to this hypothesis, inhibition of GAPDH limits the flux of glucose through glycolysis and, combined with the increase in ambient glucose concentration, causes an increase in the cytosolic concentration of 3-and 6-carbon glycolytic intermediates. These changes in metabolite concentrations then affect pathways, enzymes and processes that are implicated in the pathogenesis of diabetic complications, including the polyol pathway, the hexosamine pathway, protein kinase C, and formation of AGEs. All of these changes were attributed indirectly to the accumulation of triose phosphates as a result of partial inactivation of GAPDH by poly-ADPribosylation. In studies on aortic endothelial cells in vitro, the inhibition of GAPDH could be prevented by increased expression of uncoupling protein UCP-1, indicating that a high redox potential across the inner mitochondrial membrane (hyperpolarization) and reduction of the electron transport chain contributed to the increase in mitochondrial ROS production during hyperglycemia.
Based on the detection of increased levels of 2SC in muscle protein in diabetes, we speculated that oxidative stress and inhibition of electron transport during hyperglycemia might lead to an increase in concentration of Krebs cycle intermediates in mitochondria, and that, among these, fumarate, through formation of 2SC, might contribute to the inactivation of GAPDH in diabetes. We show here that fumarate concentration is significantly increased in muscle of diabetic rats and that the decrease in specific activity of GAPDH in diabetic muscle can be explained, at least in part, by increased chemical modification of cysteine residues by fumarate. We describe this process as succination of protein (in order to distinguish it from succinylation in which an amide or ester bond is formed) and propose that 2SC may be a useful biomarker of mitochondrial stress in diabetes. (12) . The analyses were conducted on a HP 6890 GC/MS using a Zebron ZB-5w/Guardian column (Phenomenex, Torrance, CA). Nonanoic acid was used as internal standard.
RESEARCH DESIGN AND METHODS

Materials
Quantification of 2SC in Muscle
Protein by UPLC MS/MS. An amount of homogenate containing 1 mg protein was precipitated with an equal volume of 20% cold trichloroacetic acid (TCA). The supernatant was decanted and the precipitated protein was hydrolyzed in 6 M HCl containing 13 C 3 , 15 N-2SC and d 8 -lysine internal standards for 1 hr at 150 ºC. Samples were dried under vacuum, then dissolved in 200 µl of 5 mM NFPA. A 20 µl (100 µg) aliquot of protein hydrolysate was injected on a Waters C18 Acquity column (2.1 mm X 50 mm, 1.7 µm) interfaced to a Waters Premier UPLC ESI-MS/MS system. The mobile phases were solvent A (5mM NFPA) and solvent B (100% acetonitrile). 2SC was eluted using a linear gradient from 10 to 40% B over 4.2 minutes at a flow rate of 0.2 µl/min and a column temperature of 30 ºC. The mass spectrometer was used in positive ion mode, and quantitative analysis was in the multiple reaction monitoring (MRM) mode. Collision gas (nitrogen) pressure was 10 Pa, the capillary voltage was 3.4 kV, the cone voltage was 22 V, the collision energy was 20 V, and the source and desolvation temperatures were 100 ºC and 350 ºC, respectively. The MRM transitions monitored were: 2SC, m/z 238>174; U- 13 Quantification was performed by isotope dilution mass spectrometry based on standard curves. The 2SC concentration was normalized to the lysine content of the samples. Immunoprecipitation and MS Analysis of GAPDH from Rat Muscle. Muscle homogenate (1 mg protein) was diluted into 300 µl of RIPA buffer (50 mM TrisHCl, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, pH 7.4). Protease inhibitor cocktail (10 µl, Sigma-Aldrich) was added, and the samples were pre-cleared by incubation with 6 µl of Protein A/G agarose beads, with rotation for 30 min at room temperature. After centrifugation at 10,000 rpm for 2 min, the supernatant was transferred to a fresh centrifuge tube, followed by further incubation with 6 µg of anti-GAPDH antibody for 3 hr at room temperature. Protein agarose A/G beads (20 µl) were then added, followed by incubation for 1 hr at room temperature. The beads were washed three times by suspension in 0.5 M NaCl in 50 mM phosphate buffer, pH 7.4, followed by centrifugation at 10,000 rpm for 2 min.
The agarose beads from the immunoprecipitation were suspended in SDS denaturing buffer (5 µl, 10% SDS, 20% glycerol, 25 mM TRIS-HCl and 5% 2-mercaptoethanol), then boiled for 10 min at 95 ºC. Following centrifugation, the supernatant was loaded onto a 10% (BioRad, Hercules CA) precast gel and electrophoresed at 200 V for 50 min. The gel was stained with Bio-Safe Coomassie (BioRad, Hercules, CA) and GAPDH bands were manually excised for digestion. The excised bands were placed into silicon coated 1.5 ml plastic centrifuge tubes and washed overnight in methanol/acetic acid (1:1, 300 µl). The protein from the gel was digested and extracted, as described by Kinter and Sherman (13) . A 10 µl aliquot of peptides extracted from a gel piece was analyzed by UPLC ESI-MS/MS, as described above. Peptide Profiling by Matrix-Assisted Laser Desorption/Ionization Time-ofFlight Mass Spectrometry (MALDI-TOF MS) Analysis. Mass and product ion mass spectra of peptides were acquired on a Brucker Daltonics (Billerica, MA) Ultraflex 2 MALDI-TOF mass spectrometer, using a matrix solution containing 7 mg of α-cyano-4-hydroxycinnamic acid (HCCA) in 1 ml of 90% acetonitrile. Samples were desalted using a µC18 Zip Tip (Millipore Corporation, Bedford, MA) and eluted onto the target plate with 2 µl of matrix solution. Mass spectra were recorded in the positive ion reflector mode scanning from 800-4000 m/z. Ions of interest were selected and subjected to product ion analysis using the LIFT cell to confirm identity. Data were collected so the target peptide mass envelope had an intensity of 3000.
RESULTS
Inhibition of Rabbit Muscle GAPDH by
Fumarate. To examine the effect of fumarate on GAPDH activity, GAPDH was incubated with fumarate at a range of concentrations or with succinate as a control for 24 hr at 37 ˚C (Fig 1A) . GAPDH enzyme activity was inhibited by fumarate in a time and concentrationdependent manner. Approximately 20% of GAPDH activity was lost by incubation with 0.5 mM fumarate for 24 hr, and 100% activity was lost in incubations with 500 mM fumarate at 24hr. Succinate had no effect on enzyme activity, while 1 mM N-ethylmaleimide completely inactivated the enzyme in 10 min (Fig. 1A) . As shown in Fig. IB (Fig. 3B and 3C ). There was no evidence of modification of Cys-281 in peptide #32 (Fig. 3D) , either in this experiment or at any other concentration of fumarate studied (Fig. 4, top line) .
The fractional loss of native peptides #17 and #26, compared to a reference peptide (A 19 AFNSGK 25 ) from GAPDH, is shown as a function of fumarate concentration in Fig. 4 . The total of 55% and 40% losses of peptides #17 and #26, respectively, in incubations with 500 mM fumarate for 24 hr (Fig. 4) , was consistent with the estimated total extent of modification of the enzyme, ~1 mol 2SC/mol subunit (Fig. 2) . Confirmation of Peptide Identity and Specificity of Modification by ESI QTOF. A sample of tryptic peptides from incubations with 50 mM fumarate for 24 hr was fractionated by reversed phase HPLC and analyzed by QTOF mass spectrometry. Based on the fragment ion spectra, the doubly charged ion m/z 963.99, identified as peptide #17, contained a 2SC adduct on the y 11 ion, but not on the y 7 ion (Fig 5A) , indicating selective modification of Cys-149, the active site cysteine residue. The doubly charged ion m/z 808.42, identified as peptide #26, contained a 2SC adduct on the y 2 ion (Fig 5B) , indicating modification at Cys-244.
2SC and Fumarate Concentrations Increase and the Specific Activity of GAPDH Decreases in Diabetic Skeletal
Muscle. To assess the role of 2SC in inhibition of GAPDH activity in diabetes, gastrocnemius muscle was obtained from streptozotocin-induced diabetic rats and age-matched control animals. Both 2SC and fumarate were significantly increased in diabetic vs. control muscle tissue ( Fig.  6A and 6B ), while GAPDH specific activity was decreased ~25% in diabetic vs. control animals (Fig. 6C ). There was a significant inverse correlation between the 2SC content of total muscle protein and the specific activity of GAPDH ( Fig  6D) . While GAPDH is only a small fraction of total cellular fraction, these experiments suggested that fumarate might have a role in inactivation of GAPDH in diabetes. Succination of GAPDH in Muscle of Diabetic Rats. To determine the extent of 2SC formation on GAPDH in vivo, GAPDH was immunoprecipitated from control and diabetic rat muscle, electrophoresed under denaturing conditions, stained with Coomassie blue, then digested in gel with trypsin. Because the quantities of protein available were insufficient for QTOF analysis and sequencing, we applied two different methods to demonstrate that GAPDH was modified in vivo and that the extent of modification was increased in diabetes. First, both of the 2SC-peptides were detectable by UPLC ESI-MS/MS in GAPDH isolated from muscle. As shown in Fig. 7 , the ratio of the 2SC-peptide:pyridylethyl(PE)-peptide was increased for both peptides #17 and #26 from diabetic vs. control muscle. The data are presented as a ratio since they are only an approximation of the relative extent of 2SC modification of GAPDH since the 2SC-and PE-peptide may not have the same ESI-MS/MS response factors. As observed for the relationship between the 2SC content of total muscle protein and the specific activity of GAPDH (Fig. 6D) , there was a significant inverse correlation between the peptide ratios in Fig. 7 and the specific activity of GAPDH (p < 0.01 for peptide #17 and p < 0.05 for peptide #26). As in Fig. 3D , PE-peptide #32 was present, but there was no detectable signal for 2SC-modified peptide #32 in GAPDH isolated from muscle protein (data not shown).
Analysis of peptides by MALDI-TOF mass spectrometry (Fig. 8 ) also showed the presence of 2SC on peptides #17 and #26 in GAPDH isolated from control and diabetic animals; peptide #32 was too large for analysis on our MALDI-TOF mass spectrometer. The signal strength for the 2SC-peptides was not strong enough for sequence analysis, but MALDI-TOF provides high resolution MS identification of the peptides. While MALDI-TOF is not considered as quantitative a technique as ESI/MS/MS mass spectrometry, the increase in relative signal strength for the 2SC peptides for GAPDH from diabetic vs. control muscle by MALDI-TOF analysis is consistent with the results of the LC-MS analysis (Fig. 7) . The ratio of modified to unmodified peptide was also correlated inversely with the specific activity of GAPDH in the muscle samples, (p < 0.05), consistent with increased modification of peptides in GAPDH isolated from muscle of diabetic vs. control rats.
DISCUSSION
Specificity of Modification and Inactivation of GAPDH by Fumarate.
The origin of the present work was the discovery of 2SC in tissue proteins and the observation that 2SC was increased in muscle proteins of diabetic rats (7). While studying reactions of fumarate with proteins, we learned that fumarate inhibited several sulfhydryl enzymes in vitro, including GAPDH, glucose-6-phosphate dehydrogenase and alcohol dehydrogenase. We focused on GAPDH because of Brownlee's hypothesis that inhibition of this enzyme and the resultant increase in glycolytic intermediates might explain alterations in critical enzymes and pathways implicated in the development of complications in diabetes (1, 9): the polyol, protein kinase C and hexosamine pathways and AGE formation. Although muscle is not considered a significant site for development of diabetic complications, it was chosen for this study because of availability of a significant mass of homogeneous tissue, for example, in comparison to microvascular endothelial cells. Muscle metabolism is also significantly altered in diabetes, and there is increasing evidence for defects in mitochondrial metabolism in muscle in diabetes (14, 15) . Thus, analysis of muscle might serve as a model for studies on mitochondrial stress and dysfunction and development of complications in other tissues.
GAPDH is a tetrameric enzyme with four free sulfhydryl groups per subunit; one of these, Cys-149 in the active site, is a nucleophilic residue and forms a thiohemiacetal linkage with the substrate G3P. The inactivation of rabbit muscle GAPDH by fumarate was readily demonstrated in vitro (Fig. 1) . Complete inactivation of free enzyme by 500 mM fumarate at 24 hr was accompanied by formation of ~1 mole 2SC/mol subunit (3.5 mol/mol GAPDH; Fig. 2) . Analysis of tryptic peptides indicated approximately equal modification of the active site Cys-149, and of a peripheral cysteine residue, Cys-244 (Fig. 3) . Cys-244, like Cys-149, is known to be a nucleophilic residue in GAPDH; it is the primary site of covalent modification of GAPDH by the lipophilic compounds, hydroxynonenal (16) and palmitoyl-CoA (17) , confirming its reactivity with electrophiles. Modification of this cysteine by palmitate and hydroxynonenal also inhibits enzyme activity, suggesting that modification of Cys-149 or Cys-244 by fumarate is mutually exclusive and that modification at either site inactivates the enzyme. While the other two cysteine residues in GAPDH did not react measurably with fumarate under experimental conditions, all 16 cysteines reacted rapidly with low concentrations of NEM, suggesting that charge-charge interactions restrict modification of the protein by fumarate.
Cys-149 and Cys-244 were also identified as sites of 2SC formation in GAPDH isolated from rat muscle. A significant increase in 2SC-modification of these cysteine residues in diabetic muscle was detectable by both UPLC ESI-MS/MS and MALDI-TOF MS analysis ( Fig. 7 & 8 Fig. 8 ) is consistent with a 25% modification and decrease in specific activity of the muscle enzyme in diabetes. The loss of activity of GAPDH in diabetic compared to control muscle (25%; Fig. 6B ) was less than might be expected from the 6-7 fold increase in fumarate (Fig. 6C ) and 2SC concentration (Fig. 6A) . However, some 2SC is detectable in GAPDH of control animals (Figs. 7 & 8) . Assuming 4% 2SC content and 96% of the maximal specific activity of GAPDH in control animals, a 6-fold increase in 2SC in diabetes would be consistent with a 25% decrease in specific activity of the enzyme. Although this discussion is meant to be illustrative, rather than quantitative, it points out the need to apply more rigorous quantitative proteomic techniques to validate the quantitative role of fumarate in protein modification in diabetes. Endogenous Defenses. Glutathione (GSH), which is present at millimolar concentrations in cells, could be important in limiting succination of proteins and blunting the effects of increasing cellular fumarate concentration. However, the high pKa of the cysteine residue of GSH, ~9.0 (18), would limit its effectiveness in protecting the nucleophilic cysteine residues of GAPDH. Indeed, the rate of succination of GAPDH is ~250 faster than that of Nacetylcysteine at physiological pH (7). Despite protective mechanisms, the inactivation of GAPDH by fumarate is an observable and measurable consequence of fumarate accumulation in tissues in diabetes. Notably, the mild decrease in specific activity of GAPDH (Fig. 6 ) is consistent with a chronic, partial inhibition of glycolysis in skeletal muscle in diabetes, which may be sufficient to cause the metabolic and chemical imbalances implicated in the development of diabetic complications (1) . Oxidative Stress and Mitochondrial Dysfunction in Diabetes. The mitochondrial electron transport chain (ETC) is one of the major sources of ROS production in the cell and is implicated in both glucotoxicity to cells in culture and development of complications in diabetes (1, 10 ) . Hyperpolarization of the ETC appears to be part of the mechanism of glucotoxicity since inhibitors of the ETC enhance mitochondrial ROS production, while uncouplers and uncoupling proteins have the opposite effect (10, 19, 20) . One consequence of inhibition of the ETC would be an increase in KCIs, particularly those oxidized by NAD-dependent dehydrogenases. Under such conditions, the full spectrum of Krebs cycle intermediates would probably accumulate in the mitochondrion, as happens in muscle mitochondria during prolonged, strenuous exercise when inhibition of the ETC and oxidative stress are mediated by exercise-induced oxygen debt or hypoxia (21, 22). These intermediates, including fumarate, would then migrate into the cytosol through one of several passive mitochondrial carboxylic acid transporters (23, 24) .
Fumarate may have a unique role as a chemical communicator between the mitochondrion and the cytosol and other subcellular compartment during mitochondrial stress -we use the word stress, rather than dysfunction, here because the mitochondrial response in diabetes, like that in exercise, may be a perfectly reasonable response to stress, not necessarily an indication of dysfunction. During prolonged exercise, for example, the accumulation of fumarate and other KCIs is the result of lack of oxygen, not mitochondrial dysfunction.
In diabetes, the mitochondrial stress and accumulation of fumarate may result from the excess concentration of carbohydrate and lipid substrates.
A number of mechanisms have been described for inactivation of thiol enzymes in diabetes and other diseases, including direct oxidation of Cys residues, glutathionylation, nitrosation, poly-ADPribosylation, reaction with intermediates in formation of AGEs and ALEs, and now reaction with fumarate to form 2SC. The relative contribution of these reversible and irreversible mechanisms to inactivation of various enzymes, including GAPDH, remains to be determined. It seems likely that the accumulation of fumarate might occur at an early stage of stress, in concert with the increase in ROS production, and that succination of protein by fumarate might be one mechanism for modulating the activity of extra-mitochondrial enzymes, such as GAPDH, limiting the flux of glycolytic intermediates into the Krebs cycle in diabetes. In this context, succination of protein may be one of the early indicators of glucotoxicity, possibly a protective response preceding changes in mitochondrial permeability and swelling and increased generation of reactive oxygen species, processes that set the stage for apoptosis and cell death. Prolonged oxidative stress could also overwhelm antioxidant defenses, leading to DNA damage and eventually to activation of poly-ADP-ribose polymerase (PARP), which may also contribute to inactivation of GAPDH (8) .
In this study we have addressed only a single enzyme, GAPDH, and its response to modification by fumarate. There are obviously a number of other sulfhydryl enzymes and proteins that are likely targets for modification by fumarate (7) Figure 1 . Kinetics of GAPDH Inhibition by Fumarate in vitro. A) GAPDH (1 mg/ml) was incubated in the presence of fumarate (0.5, 5, 50, and 500 mM), succinate (5 mM) or NEM (5 mM) in 50 mM phosphate buffer, pH 7.4, 37 ºC. B) GAPDH (1 mg/ml) was incubated in the presence of 50 mM fumarate with or without 1 mM coenzyme and/or 1mM substrate in 50 mM phosphate buffer, pH 7.4, 37 ºC. Data are means ± SD from 3 independent experiments. Figure 2 . Kinetics of formation of 2SC during Incubation of GAPDH with Fumarate. A) GAPDH (1 mg/ml) was incubated with various concentrations of fumarate (0.5, 5, 50 and 500 mM) in 50 mM phosphate buffer, pH 7.4, at 37ºC for 24 hr, then dialyzed and hydrolyzed in 6 M HCl for quantification of 2SC by amino acid analysis. B) Levels of 2SC ( Fig. 2A) correlate with the percent inhibition of GAPDH (Fig. 1A) . Data are means ± SD from 3 independent experiments (r 2 = 0.78, p < 0.01). 
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